HS3ST2

Across TCGA pan-cancer cohorts, HS3ST2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated HS3ST2 data layer compared with 23 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher HS3ST2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated HS3ST2 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

HNSC, SCLC, and LUAD are the cancer types where HS3ST2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.098	0.768	<.001	48	view →
SCLC	OS	Median	All	0.151	0.714	<.001	36	view →
LUAD	DFS	Median	III,IV	0.036	0.673	<.001	11	view →
STAD	DFS	Median	II,III,IV	1.000	0.373	.016	9	view →
UCEC	DFS	Median	All	1.000	0.631	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

HS3ST2–HNSC (OS)

Open the HNSC breakdown →